Johnson & Johnson’s RYBREVANT®▼ (amivantamab) plus chemotherapy delivers median overall survival of nearly three years in EGFR exon 20 insertion mutation-positive non-small cell lung cancer

Phase 3MixedRYBREVANTcarboplatin-pemetrexedPositive

AI Analysis

Summary

Johnson & Johnson announced Phase 3 PAPILLON final OS analysis showing amivantamab plus chemotherapy achieved median OS of 34.3 months versus 27.9 months with chemotherapy alone in EGFR exon 20 insertion-positive NSCLC, representing a numerical but statistically non-significant improvement.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Not Met

Outcome Details

Median OS of 34.3 months with amivantamab plus chemotherapy vs 27.9 months with chemotherapy alone (HR 0.87, 95% CI 0.66-1.14, p=0.307). Numerical OS benefit of 6.4 months but not statistically significant.

Importance:6/10

Sentiment:

0.30

Phase 3 resultsEGFR exon 20 insertionNSCLCoverall survivalamivantamabPAPILLON study

Related Companies

$JNJ

Read the original article

Published by GlobeNewswire Pharma on September 14, 2026 8:10 AM

Read Original